Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

NCT05396859 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Decitabine and Cedazuridine
DRUG: Entrectinib
OTHER: Laboratory Biomarker Analysis

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]